Value of urapidil combined with benazepril on patients with coronary heart disease and heart failure
Objective To explore the value of urapidil combined with benazepril on patients with coronary heart disease complicated with heart failure.Methods A total of 118 patients with coronary heart dis-ease and heart failure who were admitted from November 2020 to November 2023 were studied.They were ran-domly divided into an observation group(n=59,treated with urapidil combined with benazepril)and a control group(n=59,treated with benazepril alone)using random number table method.After one month of treatment,the efficacy,cardiac function,NT-proBNP levels,exercise tolerance,and occurrence of adverse reactions were compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group(x2=4.827,P<0.05).Compared with before treatment,the left ventricular ejection frac-tion(LVEF)and stroke volume(SV)in both groups increased after treatment,with the observation group showing higher LVEF and SV(t=2.345,3.198,P<0.05).The left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)decreased in both groups after treatment compared to before treatment,and the LVEDD and LVESD in the observation group were lower(t=2.265,2.007,P<0.05).Com-pared with before treatment,the 6-minute walking distance(6MWT)increased after treatment in both groups,and the 6MWT was higher in the observation group(t=2.018,P<0.05).The level of NT-proBNP in both groups after treatment decreased compared with before treatment,with the NT-proBNP in the observation group being lower(t=3.575,P<0.05).There was no statistical significance in the total incidence rate of adverse reac-tions between the groups(P>0.05).Conclusion Urapidil combined with benazepril has a high application value for patients with coronary heart disease complicated by heart failure.
NETL
NSTL
万方数据
